IDO1/TDO-IN-4 - ≥99% , CAS No.461424-21-5

CAS: 461424-21-5 Cat. No.: I649092 Fórmula: C₁₄H₁₀N₄ Peso molecular: 234.26

GRADE & PURITY ≥99%

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Visão geral

IDO1/TDO-IN-4 is a potent IDO1/TDO dual inhibitor, with IC 50 values of 3.53 μM (IDO1) and 1.15 μM (TDO). IDO1/TDO-IN-4 forms hydrogen bond with IDO1 , and π−π stacking interaction with TDO. IDO1/TDO-IN-4 can be used in the research of depression, and depression-induced infectious, metabolic, and autoimmune disorders

In Vitro

IDO1/TDO-IN-4 (compound 28, 0-2 μM, 1 h) inhibits the LPS-induced activation of BV2 microglial cells (determined by morphological changes). IDO1/TDO-IN-4 (0-2 μM, 1 h) inhibits the generation of pro-inflammatory factors and promotes the expression of IL-10. IDO1/TDO-IN-4 (0-2 μM, 1 h) decreases the expression of IDO1 and prevents the excessive degradation of tryptophan via the kynurenine pathway. MCE has not independently confirmed the accuracy of these methods. They are for reference only. RT-PCRCell Line: 100 ng/mL LPS-induced BV2 microglial cells Concentration: 0, 0.25, 0.5, 1, 2 μM Incubation Time: 1 h Result: Inhibited the generation of COX2, iNOS, TNF-α, and IL-1β. Increased the level of IL-10.

In Vivo

IDO1/TDO-IN-4 (compound 28, i.p., 20 mg/kg, at day 1, 2, 3) rescues LPS-induced neuroinflammation and depressive-like behavior in mice . IDO1/TDO-IN-4 (I.p. or i.v., 20 mg/kg) displays high exposure and a high volume of distribution at the steady state in normal mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 2 mg/kg LPS-induced depressive mice Dosage: 20 mg/kg Administration: Intraperitoneal injection (i.p.), at day 1, 2, 3. Result: Attenuated microglial activation significantly. Decreased inflammatory factors in the hippocampus, such as TNF-α, IL-1β, and iNOS. Downregulated LPS-induced overexpression of IDO1. Animal Model: Male C57BL/6J mice (pharmacokinetic assay) Dosage: 20 mg/kg Administration: Intraperitoneal injection and intravenous injection Result: Pharmacokinetic profile of IDO1/TDO-IN-4 (compound 28) pharmacokinetic property T 1/2 (h) T max (h) C max (ng/mL) bioavailability F (%) i.v./i.p. 2.31/0.77 0.25 5543.99/3878 52.55

Form:Solid

IC50& Target:IDO1 3.53 μM (IC 50 )

Specifications

Especificações e pureza

≥99%

Mecanismos bioquímicos e fisiológicos

IDO1/TDO-IN-4 is a potent IDO1/TDO dual inhibitor, with IC 50 values of 3.53 μM (IDO1) and 1.15 μM (TDO). IDO1/TDO-IN-4 forms hydrogen bond with IDO1 , and π−π stacking interaction with TDO. IDO1/TDO-IN-4 can be used in the research of depression, and dep

Condições de armazenamento de armazenamento

Store at -20°C

Enviado em

Ice chest + Ice pads

Este produto requer transporte de cadeia fria. Serviços terrestres e outros serviços econômicos não estão disponíveis.

Tipo de ação

INHIBITOR

Pureza

≥99%

Nomes e identificadores

• Peso molecular: 234.26

Propriedades químicas e físicas

• Solubilidade: DMSO : 125 mg/mL (533.60 mM; ultrasonic and warming and heat to 60°C) Methanol : 16.67 mg/mL (71.16 mM; ultrasonic and warming and heat to 60°C)

Perguntas frequentes

What is the purity of this product?

This product is supplied at ≥99% purity (chemical assay). Lot-specific values are stated on the Certificate of Analysis.

How should this product be stored?

Store at ?20 °C. Freezer storage is required to maintain the specified shelf life.

How is this product shipped?

This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.

What are the CAS number, molecular formula and molecular weight?

The CAS Number is 461424-21-5, the molecular formula is C14H10N4, and the molecular weight is 234.26 g/mol.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.